US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops: bit.ly/4ifhtS7
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision: bit.ly/4jCW0Fa
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million: bit.ly/47M9M15
HelpMeSee Names Former Test Pilot Doug May as President and CEO: bit.ly/484psga
Corza Medical Launches Expanded Single-Use Custom Packs: bit.ly/47poUkX
Visara Licenses Topical Neurotrophic Keratitis Candidate from China’s Hiteck: bit.ly/482COcR
US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027: bit.ly/4838MFS
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over: bit.ly/4jphEwx
Alvotech, Advanz Submit Marketing Application to EMA for High-Dose Aflibercept Biosimilar: bit.ly/4i21VBe
US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED: bit.ly/4it47D4
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate: bit.ly/4yiDN3a
Nobel Prize for Medicine Goes to Team First to Publish Optogenetics Findings: bit.ly/4hXg0js
VEO Ophthalmics to Market the VitaPixel Visualization System for Slit Lamps: bit.ly/4ymvBPB
Japanese Regulators Accept NDA for Nanoscope’s Optogenetic Gene Therapy Candidate, Grant Priority Review: bit.ly/47TELbu
Study Indicates that Circadian Rhythm and Light May Affect IOP: bit.ly/4jW64cj
Sagent Pharmaceuticals Launches Zyogreen Ready-to-Use Indocyanine Green Dye for Injection in the US: bit.ly/4s194WV
Carrot, Maker of VR Visual Field Testing, Acquires IOL Simulation Developer GreenMan: bit.ly/4k2aEps
Glaukos Licenses Tri-specific Retinal Candidate RO-104 from RevOpsis: bit.ly/4s8ObJB
Claris Bio Establishes Corporate Headquarters in San Francisco: bit.ly/4hN6lvP
InSightVR IOL Simulator Linked to Increased Premium Lens Selection, Better Understanding: bit.ly/4hJexNC
